by DiaCarta Inc. | Jul 2, 2018 | Blog
Month: July 2018 FollowFollowFollow 1. The challenges that our clients faced Acute myeloid leukemia (AML) is an aggressive hematopoietic neoplasm characterized by an accumulation of myeloid cells in the bone marrow because of impaired differentiation and...
by DiaCarta Inc. | Jun 4, 2018 | Press Releases
Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ category ❯ Press Releases ❯ DiaCarta Named to CIO Applications’ “Top 25 Life Sciences Technology Vendors 2018” FollowFollow CIO Applications has chosen DiaCarta as one of the Top 25 Life Sciences...
by DiaCarta Inc. | Apr 16, 2018 | Press Releases
Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ category ❯ Press Releases ❯ DiaCarta and MIODx Join Forces to Develop a Diagnostic Test to Predict Patient Responses to Immunotherapy FollowFollow MIODx and DiaCarta announced today that they have...
by DiaCarta Inc. | Feb 12, 2018 | Press Releases
Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ category ❯ Press Releases ❯ DiaCarta, Ltd Raises $45 Million USD Series B Funding to Expand Its Liquid Biopsy Cancer Detection Platform & Services FollowFollow DiaCarta has announced that it...
by DiaCarta Inc. | Feb 20, 2017 | Press Releases
Press release Home ❯News & Events❯Press Releases❯ You are here ❯ Home ❯ category ❯ Press Releases ❯ DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test – ColoScape™ Real-Time PCR Kit FollowFollow DiaCarta today announced it received CE-IVD...
